See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Social Media
Natural Disasters
Stock Markets
Donald Trump
Artificial Intelligence
US Politics
MLB
Instagram
Education
South America
Democratic Party
Boxing
oncnursingnews.com image

News from oncnursingnews.com

We’ve assigned a media bias rating of unknown to oncnursingnews.com. You can read more about our methodology here.
If you want to know if oncnursingnews.com is credible or reliable, look no further. We rank oncnursingnews.com as Unknown factuality. Find out more about our methodology here.

Information about oncnursingnews.com

Where is oncnursingnews.com located?oncnursingnews.com's Website

Media Bias Ratings

Do you diasgree?
Edit bias
Learn more about Media Bias Ratings.

Factuality

Learn more about  Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about  Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top oncnursingnews.com News

Melanoma Survivor Shares Story to Encourage Pittsburghers to Prioritize Skin Health
Cancer

Melanoma Survivor Shares Story to Encourage Pittsburghers to Prioritize Skin Health

100% Center coverage: 1 sources
Melanoma, the most serious skin cancer, claims thousands of lives a year, with men dying at a higher rate because of delayed detection and treatment.See the Story
Sirtex Medical's SIR-Spheres® Y-90 Resin Microspheres Receive FDA Approval for the Treatment of Unresectable Hepatocellular Carcinoma
United States · United States

Sirtex Medical's SIR-Spheres® Y-90 Resin Microspheres Receive FDA Approval for the Treatment of Unresectable Hepatocellular Carcinoma

100% Center coverage: 1 sources
/PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of interventional oncology solutions, today announced that the U.S. Food and Drug...See the Story
FDA Grants Priority Review to TAR-200 in BCG-Unresponsive High-Risk NMIBC
United States · United States

FDA Grants Priority Review to TAR-200 in BCG-Unresponsive High-Risk NMIBC

Phase 2b SunRISe-1 trial findings supported the FDA to grant priority review to TAR-200 in BCG-unresponsive high-risk NMIBC with carcinoma in situ.See the Story

Across Cancer Types, Trispecific Antibodies Show Promise in Early Result

Innovative trispecific antibodies show promise in treating relapsed/refractory multiple myeloma and neuroendocrine carcinoma, enhancing patient outcomes and safety.EducationSee the Story

RELATIVITY-047 4-Year Update: Long-Term Outcomes in Frontline Metastatic Melanoma

Panelists discuss evolving frontline treatment strategies for metastatic melanoma, emphasizing recent clinical updates—particularly 4-year data from the RELATIVITY-047 trial—and exploring how these findings, including the benefits of nivolumab plus relatlimab, inform real-world decision-making for complex cases like BRAF-mutant disease with high tumor burden.See the Story

Neoantigen Vaccine Shows Promise In RCC-Mutated Renal Cell Carcinoma

A personalized neoantigen vaccine may be effective in patients with clear cell renal cell carcinoma, shared David A. Braun, MD, PhD.Read Article

IV Magnesium May Help Prevent Cisplatin-Induced AKI

Oncology nurses can assess patients’ risk factors and advocate for preventive strategies that protect kidney function during cisplatin therapy.Read Article

The Multidisciplinary Approach to Care for Advanced NSCLC

Panelists discuss how managing amivantamab-related adverse events like leg edema requires understanding of underlying mechanisms (hypoalbuminemia) and may benefit from albumin infusion, dose holds, or consultation with specialists for severe cases like infected scalp wounds.See the Story

Managing Dermatologic AEs With Amivantamab/Lazertinib: Updates From the COCOON Clinical Trial

Panelists discuss how the COCOON study's advanced dermatologic prophylaxis protocol, including systemic antibiotics and topical treatments, can reduce skin toxicities by 50% in patients receiving amivantamab plus lazertinib therapy.See the Story

Carotuximab/Apalutamide Shows Tolerability in Metastatic CRPC

No dose-limiting toxicities or unexpected adverse effects occurred with carotuximab/apalutamide in metastatic castration-resistant prostate cancer.See the Story

Awareness of Actionable Mutations Guides mBC Treatment Post-Endocrine

Understanding actionable mutations and educating patients on the safety profiles of targeted therapies are essential for the care of HR+, HER2United States · United StatesRead Article

Breaking News Topics Related to oncnursingnews.com

Breast Cancer icon

Breast Cancer

Cancer icon

Cancer

United States icon

United States

News
For You
SearchBlindspotLocal